• FDA grants priority review to Keytruda plus chemotherapy for lung cancer subtype

    7 monthes ago - By Healio

    The FDA granted priority review designation to a supplemental biologics license application that seeks approval of pembrolizumab for use in combination with chemotherapy as first-line treatment of metastatic squamous non-small cell lung cancer regardless of PD-L1 expression.
    The agency set a target action date of Oct. 30.
    Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
    The agent already is approved in the United States for treatment of certain patients with NSCLC, melanoma, head and neck cancer,
    Read more ...


  • Experimental drug stops Parkinson's disease progression in mice

    7 monthes ago - By ScienceDaily

    Researchers say they have developed an experimental drug, similar to compounds used to treat diabetes, that slows the progression of Parkinson's disease itself - as well as its symptoms - in mice.
    Read more ...


  • Established lung fibrosis can be reversed using diabetes drug treatment

    7 monthes ago - By News Medical

    Researchers at the University of Alabama at Birmingham have shown -; for the first time -; that established lung fibrosis can be reversed using a drug treatment that targets cell metabolism.
    Read more ...